Marc Chamberlain MD

Prior to joining Pionyr, Marc Chamberlain was Medical Director at SystImmune, Inc where he developed protocols for novel multi-valent monoclonal antibodies for first-in-human early-phase clinical trials. Before that, he served as Medical Director at Seattle Genetics following its acquisition of Cascadian Therapeutics, where he led clinical stage development of a novel HER2 tyrosine kinase inhibitor, tucatinib, through clinical proof of concept in HER2 positive metastatic breast cancer and subsequently helped to develop and execute a randomized Phase 2/3 global trial which resulted in an FDA approval. Before joining the industry, Dr. Chamberlain was a professor and academic oncologist, where he had both extensive experiences as a clinician (specializing in neuro-oncology) as well as serving as Principal Investigator on multiple trials, including cooperative group, pharma sponsored as well as investigator-initiated trials. Dr. Chamberlain received his M.D. from Columbia University, College of Physicians and Surgeons, and completed residencies/fellowships in pediatrics, neurology, and neuro-oncology at the University of California, Los Angeles, and the University of California, San Francisco. He has authored more than 500 scientific publications in major journals.